JP2018531994A5 - - Google Patents

Info

Publication number

JP2018531994A5

JP2018531994A5 JP2018534511A JP2018534511A JP2018531994A5 JP 2018531994 A5 JP2018531994 A5 JP 2018531994A5 JP 2018534511 A JP2018534511 A JP 2018534511A JP 2018534511 A JP2018534511 A JP 2018534511A JP 2018531994 A5 JP2018531994 A5 JP 2018531994A5

Authority

JP

Japan

Prior art keywords

seq

modified immunoglobulin

antigen binding

immunoglobulin molecule

use according

Prior art date

2016-09-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000000427 antigen Substances 0.000 claims description 76
• 102000036639 antigens Human genes 0.000 claims description 76
• 108091007433 antigens Proteins 0.000 claims description 76
• 238000000034 method Methods 0.000 claims description 63
• 206010028980 Neoplasm Diseases 0.000 claims description 32
• 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims description 31
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 31
• 102000044457 human DLL4 Human genes 0.000 claims description 31
• 102000058223 human VEGFA Human genes 0.000 claims description 31
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 17
• 201000011510 cancer Diseases 0.000 claims description 16
• 229960001592 paclitaxel Drugs 0.000 claims description 12
• 229930012538 Paclitaxel Natural products 0.000 claims description 10
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 7
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
• 239000003795 chemical substances by application Substances 0.000 claims description 4
• 238000011282 treatment Methods 0.000 claims description 4
• 239000004472 Lysine Chemical group 0.000 claims description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
• 206010033128 Ovarian cancer Diseases 0.000 claims description 3
• 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
• 206010066901 Treatment failure Diseases 0.000 claims description 2
• 229960000397 bevacizumab Drugs 0.000 claims description 2
• 230000003442 weekly effect Effects 0.000 claims description 2
• 108060003951 Immunoglobulin Proteins 0.000 claims 24
• 102000018358 immunoglobulin Human genes 0.000 claims 24
• 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 2
• 239000004471 Glycine Chemical group 0.000 claims 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
• 229940123237 Taxane Drugs 0.000 claims 2
• 235000009582 asparagine Nutrition 0.000 claims 2
• 229960001230 asparagine Drugs 0.000 claims 2
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 2
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 2
• 239000004475 Arginine Chemical group 0.000 claims 1
• 229960005500 DHA-paclitaxel Drugs 0.000 claims 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
• 235000004279 alanine Nutrition 0.000 claims 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
• 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
• 235000003704 aspartic acid Nutrition 0.000 claims 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
• LRCZQSDQZJBHAF-PUBGEWHCSA-N dha-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 claims 1
• 229960003668 docetaxel Drugs 0.000 claims 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
• 229940099472 immunoglobulin a Drugs 0.000 claims 1
• 238000002560 therapeutic procedure Methods 0.000 claims 1
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
• 230000002401 inhibitory effect Effects 0.000 description 10
• 150000001413 amino acids Chemical group 0.000 description 8
• 190000008236 carboplatin Chemical compound 0.000 description 8
• 229960004562 carboplatin Drugs 0.000 description 8
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 7
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
• 229940028652 abraxane Drugs 0.000 description 7
• 229960002949 fluorouracil Drugs 0.000 description 7
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 7
• 235000008191 folinic acid Nutrition 0.000 description 7
• 239000011672 folinic acid Substances 0.000 description 7
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 7
• 229960005277 gemcitabine Drugs 0.000 description 7
• 229960004768 irinotecan Drugs 0.000 description 7
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 7
• 229960001691 leucovorin Drugs 0.000 description 7
• 239000013612 plasmid Substances 0.000 description 6
• 229910052697 platinum Inorganic materials 0.000 description 6
• 230000004614 tumor growth Effects 0.000 description 6
• 208000013452 Fallopian tube neoplasm Diseases 0.000 description 5
• 230000033115 angiogenesis Effects 0.000 description 5
• 208000023965 endometrium neoplasm Diseases 0.000 description 5
• 210000000130 stem cell Anatomy 0.000 description 5
• 210000004881 tumor cell Anatomy 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 238000006467 substitution reaction Methods 0.000 description 4
• 206010014733 Endometrial cancer Diseases 0.000 description 3
• 206010014759 Endometrial neoplasm Diseases 0.000 description 3
• 229920001184 polypeptide Polymers 0.000 description 3
• 208000026087 primary peritoneal tumor Diseases 0.000 description 3
• 102000004196 processed proteins & peptides Human genes 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 201000001342 Fallopian tube cancer Diseases 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 230000000694 effects Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 238000011519 second-line treatment Methods 0.000 description 1